Supernus Secures $650 Million Senior Secured Term Loan for Merger and Refinancing
Supernus Pharmaceuticals (SUPN) secured a $650 million senior secured term loan from Citibank and other lenders on November 2, 2026. The funds will support a merger, refinance existing debt, and cover transaction costs. Interest rates are based on Term SOFR or the Base Rate plus applicable margins, varying by leverage.
How this was made
The 30-second read
Why it matters
The financing enables the planned merger and debt refinancing, improving liquidity but increasing leverage.
Market read
First‑report disclosure of a sizable merger‑related loan, likely to move SUPN stock on the day of filing.
What to watch
Interest rate environment and margin terms could affect cost of capital more than the headline amount.
Background
Supernus Pharmaceuticals filed an 8‑K announcing a $650 million senior secured term loan with Citibank and other lenders.
Ticker impact
Supernus secured a $650 million senior secured term loan to fund its merger and refinance debt.
likely upward pressure as the market prices in the fresh capital and merger funding
A large, newly disclosed loan at market terms is material for a mid‑cap biotech and typically triggers a short‑term price lift.
Market effects
Provides a precedent for biotech financing via term loans, may encourage similar deals in the sector.
Neutral to US market; limited broader regional effect.
Low; primarily relevant to US biotech investors.
Counterpoint
The loan adds leverage; if the merger fails, the debt could pressure the balance sheet.
Key entities
- companySupernus Pharmaceuticals
Biotech firm pursuing a merger, ticker SUPN.
- lenderCitibank
Lead bank on the term loan facility.
